One of the reasons for this phenomenon is that tumor cells with PBRM1 mutation facilitate the sensitivity to T-cell-mediated cytotoxicity and produce higher amounts of chemokines and these chemokines then recruit a greater number of effector T cells into the tumors, which enhances the response of ccRCC patients to immunotherapy [43]. Here, PBRM1 is linked to neoplasm.